Chlorpromazine

CHEMBL71 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

318.9 g/mol

LogP

5.2

Phase

4

The first antipsychotic medication, introduced in the 1950s, that blocks dopamine D2 receptors and multiple other neurotransmitter receptors, used for the treatment of schizophrenia, mania, nausea, and intractable hiccups. Its discovery revolutionized psychiatry and led to the deinstitutionalization of many psychiatric patients. It carries significant risks of extrapyramidal symptoms, tardive dyskinesia, metabolic effects, and sedation.

Peso molecular

318,9000 g/mol

LogP

5,20

TPSA

31,80 Å²

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Enfermedad por reflujo gastroesofágico Esquizofrenia Glaucoma Ictus Trastorno bipolar

Mecanismo de acción

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21

InChI

InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

Molecular Formula

C17H19ClN2S

HBD / HBA

- / 3

Enlaces Rotables

4

Átomos Pesados

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

The first antipsychotic medication, introduced in the 1950s, that blocks dopamine D2 receptors and multiple other neurotransmitter receptors, used for the treatment of schizophrenia, mania, nausea, and intractable hiccups. Its discovery revolutionized psychiatry and led to the deinstitutionalization of many psychiatric patients. It carries significant risks of extrapyramidal symptoms, tardive dyskinesia, metabolic effects, and sedation.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Chlorpromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL71. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2726. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

¿Busca información accesible para el paciente?

Chlorpromazine en PillFYI

Estructura

Datos Rápidos

Fórmula: C17H19ClN2S
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.